Novo Nordisk shares fall on weight-loss drug trial

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of CagriSema showed that patients on the highest dose of the drug lost 15.7% of their weight. Patients who were…